Teva Pharmaceuticals

1601 articles with Teva Pharmaceuticals

• Teva Reports Third Quarter 2020 Financial Results

  11/5/2020

  Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net revenues of $16.5-16.8 billion EBITDA of $4.7 - $4.9 billion EPS of $2.40 - $2.55 Free cash flow of $1.8 - $2.2 billion

• Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

  10/21/2020

  Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. announced that the company is collaborating with Amazon Web Services, Inc. and Onica, a Rackspace Technology company, to build and host its Digital Health Platform.

• 

  GSK vs. Teva Patent Infringement Decision Reversal Could Have Broader Implications

  10/6/2020

  In the October 2 verdict, Circuit Judge Pauline Newman said that promotional materials, press releases, product catalogs, FDA labels and witness testimony did support the “induced infringement” judgement against Teva.

• Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) Tablets in the U.S.

  10/2/2020

  Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the availability of the first Food and Drug Administration (FDA)-approved generic versions of TRUVADA ®i and ATRIPLA ®i tablets. “As the global leader in producing and supplying generics, Teva is excited to launch these medications which further our commitment to deli

• Teva to Host Conference Call to Discuss Third Quarter 2020 Financial Results at 8 a.m. ET on November 5, 2020

  10/1/2020

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter financial results, Thursday November 5, 2020 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): Uni

• 

  DOJ Charges Teva Pharmaceutical In Ongoing Generics Price-Fixing Probe

  8/26/2020

  The U.S. Department of Justice charged the Israel-based company with three counts of fixing prices to reap more than $350 million from customers through the scheme.

• Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

  8/5/2020

  The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry

• Teva Reports Second Quarter 2020 Financial Results

  8/5/2020

  Revenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion

• Teva Announces New Strategic Focus in the Japanese Market

  7/30/2020

  Japan Business Venture shifts focus to specialty assets and a portfolio of select generics that meet patients' medical needs

• Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020

  7/9/2020

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m. ET.

• Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fremanezumab-vfrm) Injection

  6/18/2020

  Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY ® (fremanezumab-vfrm) Injection Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks Pooled Phase 3 results examined changes in disability using American Headache Society guidelines TEL AVIV & PARSIPPANY, N.J.--( BUSINESS WIRE )-- Tev

• Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting

  6/15/2020

  Teva to Present New Data on AJOVY ® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting

• 

  FDA Announces Five Companies Are Recalling Diabetes Drugs Over Carcinogen Concerns

  6/12/2020

  Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.

• Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

  6/2/2020

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report , demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content. Th

• Teva Announces Virtual 2020 Annual Meeting of Shareholders

  5/26/2020

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.

• Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine

  5/25/2020

  Teva Pharmaceutical Industries Ltd. presented a wide range of important new data on AJOVY® and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology.

• Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress

  5/22/2020

  Teva Pharmaceutical Industries Ltd. announced that new data on AJOVY® and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology, being held virtually from 23-26 May 2020.

• China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

  5/18/2020

  Teva Pharmaceutical Industries Ltd., announced that the China National Medical Products Administration has approved AUSTEDO® for the treatment of chorea associated with Huntington's disease and Tardive Dyskinesia in adults, after a priority review.

• Teva Reports First Quarter 2020 Financial Results

  5/7/2020

  Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion

• Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan® (rituximab) Available in the United States for This Indication

  5/4/2020

  Teva and Celltrion Healthcare Announce the Launch of TRUXIMA ® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan ® (rituximab) Available in the United States for This Indication TRUXIMA is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)